机构：[1]Department of Oncology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005[2]Department of Oncology, Traditional Chinese Medicine‑Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315[3]Blood Disease Laboratory[4]Medical Clinical Laboratory, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005, P.R. China
The present study aimed to evaluate the diagnostic and prognostic value of Tat-interacting protein 30 (HTATIP2/TIP30) levels alone and in combination with α-fetoprotein (AFP) for the evaluation of hepatocellular carcinoma (HCC) patients. ELISA and immunohistochemical measurements on the serum and tissue of HTATIP2/TIP30 protein from HCC patients and normal controls were made. Receiver operating characteristic (ROC) curve analyses of AFP and HTATIP2/TIP30 were performed, as well as logistic regression analysis of APF combined with HTATIP2/TIP30. Log-rank analysis was used to correlate the prognosis with various levels of HTATIP2/TIP30. HTATIP2/TIP30 levels were significantly lower in the HCC group compared with the control group (4.50±2.63 vs. 9.50±2.04 ng/ml, P<0.001). ROC analysis revealed an optimal cut-off point at 7.27 ng/ml HTATIP2/TIP30 for separating the HCC from the control groups. The sensitivity and specificity were 84.6 and 93.7% (P<0.001), respectively. ROC areas of HTATIP2/TIP30 (0.928, P<0.001) were significantly higher than those for AFP (P<0.001). The area under the curve of the HTATIP2/TIP30 and AFP combination was 0.950 (P<0.001). Log-rank tests revealed that the recurrence-free survival time of the group with HTATIP2/TIP30>5.71 ng/ml was significantly higher than that of the control group (P<0.001). This is the first study to demonstrate that HTATIP2/TIP30 levels in serum may be an effective biomarker for the diagnosis and prognosis of HCC.
基金：
the Science and Technology Department of Hunan Province Science and Technology Plan (grant no. 2014FJ6066) and the Science and Technology Program of Hunan Provincial Health Department (grant no. B2014-087).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2016]版：
大类|4 区医学
小类|4 区肿瘤学
最新[2025]版：
大类|4 区医学
小类|4 区肿瘤学
第一作者：
第一作者机构：[1]Department of Oncology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005[2]Department of Oncology, Traditional Chinese Medicine‑Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315
通讯作者：
通讯机构：[1]Department of Oncology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005[2]Department of Oncology, Traditional Chinese Medicine‑Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315[*1]Department of Oncology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, 61 Jiefang Xi Road, Furong, Changsha, Hunan 410005, P.R. China[*2]Department of Oncology, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, No. 13 Shiliu Gang Road, Haizhu, Guangzhou, Guangdong 510315, P.R. China
推荐引用方式(GB/T 7714)：
Fan Sha-Sha,Liao Chu-Shu,Cao You-De,et al.A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma.[J].Oncology letters.2017,13(6):4208-4214.doi:10.3892/ol.2017.6024.
APA：
Fan Sha-Sha,Liao Chu-Shu,Cao You-De,Xiao Pei-Ling,Deng Tan...&Duan Hua-Xin.(2017).A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma..Oncology letters,13,(6)
MLA：
Fan Sha-Sha,et al."A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma.".Oncology letters 13..6(2017):4208-4214
